Mitsubishi Tanabe Pharma Corporation – Product Pipeline Review – 2012

Abstracts
Contents

Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2012

Summary

Global Market Direct’s pharmaceuticals report, “Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2012” provides data on the Mitsubishi Tanabe Pharma Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Mitsubishi Tanabe Pharma Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from Mitsubishi Tanabe Pharma Corporation and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

Mitsubishi Tanabe Pharma Corporation - Brief Mitsubishi Tanabe Pharma Corporation overview including business description, key information and facts, and its locations and subsidiaries.
Review of current pipeline of Mitsubishi Tanabe Pharma Corporation human therapeutic division.
Overview of pipeline therapeutics across various therapy areas.
Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
Product profiles for late stage and clinical stage products of Mitsubishi Tanabe Pharma Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
Recent updates of the Mitsubishi Tanabe Pharma Corporation’s pipeline in the last quarter.
Key discontinued and dormant projects.
Latest news and deals relating to the products.

Reasons to buy

Evaluate Mitsubishi Tanabe Pharma Corporation’s strategic position with total access to detailed information on its product pipeline.
Assess the growth potential of Mitsubishi Tanabe Pharma Corporation in its therapy areas of focus.
Identify new drug targets and therapeutic classes in the Mitsubishi Tanabe Pharma Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
Exploit collaboration and partnership opportunities with Mitsubishi Tanabe Pharma Corporation.
Avoid Intellectual Property Rights related issues.
Explore the dormant and discontinued projects of Mitsubishi Tanabe Pharma Corporation and identify potential opportunities in those areas.

Keyword

Current R&D Portfolio of Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation - Key Therapeutics; Mitsubishi Tanabe Pharma Corporation - Pipeline Overview and Promising Molecules; Mitsubishi Tanabe Pharma Corporation - News; Mitsubishi Tanabe Pharma Corporation - Latest Updates; Mitsubishi Tanabe Pharma Corporation - Pipeline; Mitsubishi Tanabe Pharma Corporation - Discontinued/Dormant Projects

Mitsubishi Tanabe Pharma Corporation Snapshot
Mitsubishi Tanabe Pharma Corporation Overview
Key Information
Key Facts
Mitsubishi Tanabe Pharma Corporation – Research and Development Overview
Key Therapeutic Areas
Mitsubishi Tanabe Pharma Corporation – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Mitsubishi Tanabe Pharma Corporation – Pipeline Products Glance
Mitsubishi Tanabe Pharma Corporation – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Mitsubishi Tanabe Pharma Corporation Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Mitsubishi Tanabe Pharma Corporation – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Mitsubishi Tanabe Pharma Corporation – Drug Profiles
AST-120
  Product Description
  Mechanism of Action
  R&D Progress
BK-4SP
  Product Description
  Mechanism of Action
  R&D Progress
Cariprazine
  Product Description
  Mechanism of Action
  R&D Progress
CTA018
  Product Description
  Mechanism of Action
  R&D Progress
Daliresp
  Product Description
  Mechanism of Action
  R&D Progress
EVP-6124
  Product Description
  Mechanism of Action
  R&D Progress
GB-1057
  Product Description
  Mechanism of Action
  R&D Progress
Maintate
  Product Description
  Mechanism of Action
  R&D Progress
MCI-196
  Product Description
  Mechanism of Action
  R&D Progress
MP-124
  Product Description
  Mechanism of Action
  R&D Progress
MP-136
  Product Description
  Mechanism of Action
  R&D Progress
MP-157
  Product Description
  Mechanism of Action
  R&D Progress
MP-435
  Product Description
  Mechanism of Action
  R&D Progress
MP-435 + Methotrexate
  Product Description
  Mechanism of Action
  R&D Progress
MP-513
  Product Description
  Mechanism of Action
  R&D Progress
MP-513 + Metformin
  Product Description
  Mechanism of Action
  R&D Progress
MP-513 + Sulfonylurea
  Product Description
  Mechanism of Action
  R&D Progress
MP-513 + Thiazolidinedione
  Product Description
  Mechanism of Action
  R&D Progress
MT-1303
  Product Description
  Mechanism of Action
  R&D Progress
MT-3995
  Product Description
  Mechanism of Action
  R&D Progress
MT-7716
  Product Description
  Mechanism of Action
  R&D Progress
NK-104
  Product Description
  Mechanism of Action
  R&D Progress
Radicut
  Product Description
  Mechanism of Action
  R&D Progress
Remicade
  Product Description
  Mechanism of Action
  R&D Progress
Simponi
  Product Description
  Mechanism of Action
  R&D Progress
TA-7284
  Product Description
  Mechanism of Action
  R&D Progress
TA-8995
  Product Description
  Mechanism of Action
  R&D Progress
Talion
  Product Description
  Mechanism of Action
  R&D Progress
Venoglobulin-IH
  Product Description
  Mechanism of Action
  R&D Progress
Mitsubishi Tanabe Pharma Corporation – Pipeline Analysis
Mitsubishi Tanabe Pharma Corporation – Pipeline Products by Therapeutic Class
Mitsubishi Tanabe Pharma Corporation – Pipeline Products By Target
Mitsubishi Tanabe Pharma Corporation – Pipeline Products by Route of Administration
Mitsubishi Tanabe Pharma Corporation – Pipeline Products By Mechanism of Action
Mitsubishi Tanabe Pharma Corporation – Recent Pipeline Updates
Mitsubishi Tanabe Pharma Corporation - Dormant Projects
Mitsubishi Tanabe Pharma Corporation - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
MCC-847
MCC-977
MCC-135
MCC-555
MCI-196
TA-5493
TA-5538
TA-6666
Y-700
Mitsubishi Tanabe Pharma Corporation – Company Statement
Mitsubishi Tanabe Pharma Corporation – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Mitsubishi Tanabe Pharma Corporation, Deals Summary
Mitsubishi Tanabe Pharma Corporation, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Cytochroma Secures $44 Million In Series C Financing
Partnerships
Vertex Pharma Enters Into Agreement With Mitsubishi Pharma
Synageva BioPharma Extends Co-Development Agreement With Mitsubishi Tanabe Pharma
Medicago Enters Into Co-Development Agreement With Mitsubishi Tanabe Pharma For Vaccines
Mitsubishi Tanabe Pharma Enters Into Co-Marketing Agreement With Daiichi Sankyo For MP-513 And TA-7284
Synageva BioPharma Enters Into Research Agreement With Mitsubishi Tanabe Pharma
Mitsubishi Tanabe Pharma Enters Into Co-Development Agreement With Kyoto University
Mochida Pharma Enters Into Co-Marketing Agreement With Mitsubishi Tanabe Pharma
deCODE biostructures Expands Research Agreement With Mitsubishi Tanabe Pharma
Affectis Pharma Enters Into Drug Discovery Collaboration With Mitsubishi Tanabe
GlaxoSmithKline Enters Into Co-Promotion Agreement with Mitsubishi Tanabe Pharma
Cellumen Enters Into Co-Development Agreement With Mitsubishi Tanabe Pharma
Mitsubishi Tanabe Enters Into Co-Marketing Agreement With Bayer Yakuhin
Mitsubishi Tanabe Amends Its Agreement With Novartis Pharma
Medarex Enters Into Research Agreement With Mitsubishi Pharma
Alfresa Pharma Enters Into Co-Marketing Agreement With Mitsubishi Tanabe
Alfresa Pharma Enters Into Co-Development Agreement With Mitsubishi Tanabe
Discovery Partners Enters Into Co-Development Agreement With Mitsubishi Pharma
Merger
Tanabe Seiyaku And Mitsubishi Pharma Complete Merger
Licensing Agreements
Kureha Enters Into Licensing Agreement With Mitsubishi Tanabe
Mitsubishi Tanabe Enters Into License Agreement With R-Tech Ueno
Gedeon Richter Enters Into Licensing Agreement With Mitsubishi Pharma
Nuron Biotech Enters Into Licensing Agreement With Mitsubishi Tanabe For HibTITER
Mitsubishi Tanabe Pharma Enters Into Licensing Agreement With Toray For TRK-820
Dong-A Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For TALION
Daiichi Sankyo Enters Into Sub-Licensing Agreement With Mitsubishi Tanabe Pharma
Kowa Enters Into A Licensing Agreement With Taiwan Tanabe Seiyaku And P.T. Tanabe Indonesia
BioInvent Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma
Vertex Pharma Amends Agreement With Mitsubishi Tanabe Pharma
Mitsubishi Tanabe Enters Into Licensing Agreement With EnVivo Pharma
Mitsubishi Tanabe Enters Into Licensing Agreement With Cytochroma
Mitsubishi Tanabe Enters Into License Agreement With Maruho
Crucell And DSM Enter Into Licensing Agreement With Mitsubishi
Mitsubishi Tanabe Enters Into License Agreement With Centocor
Acquisition
Mitsubishi Tanabe Increases Its Stake In Choseido Pharma
Astellas Pharma Sells Hoshienu Pharma To Choseido Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Mitsubishi Tanabe Pharma Corporation, Key Information
Mitsubishi Tanabe Pharma Corporation, Key Facts
Mitsubishi Tanabe Pharma Corporation – Pipeline by Indication, 2012
Mitsubishi Tanabe Pharma Corporation – Pipeline by Stage of Development, 2012
Mitsubishi Tanabe Pharma Corporation – Monotherapy Products in Pipeline, 2012
Mitsubishi Tanabe Pharma Corporation – Combination Treatment Modalities in Pipeline, 2012
Mitsubishi Tanabe Pharma Corporation – Filed, 2012
Mitsubishi Tanabe Pharma Corporation – Phase III, 2012
Mitsubishi Tanabe Pharma Corporation – Phase II, 2012
Mitsubishi Tanabe Pharma Corporation – Phase I, 2012
Mitsubishi Tanabe Pharma Corporation – Pre-Clinical, 2012
Mitsubishi Tanabe Pharma Corporation – Pipeline By Therapeutic Class, 2012
Mitsubishi Tanabe Pharma Corporation - Pipeline By Target, 2012
Mitsubishi Tanabe Pharma Corporation – Pipeline By Route of Administration, 2012
Mitsubishi Tanabe Pharma Corporation – Pipeline Products By Mechanism of Action, 2012
Mitsubishi Tanabe Pharma Corporation – Recent Pipeline Updates, 2012
Mitsubishi Tanabe Pharma Corporation - Dormant Developmental Projects,2012
Mitsubishi Tanabe Pharma Corporation - Discontinued Pipeline Products, 2012
Mitsubishi Tanabe Pharma Corporation, Other Locations
Mitsubishi Tanabe Pharma Corporation, Subsidiaries
Mitsubishi Tanabe Pharma Corporation, Deals Summary
Cytochroma Secures $44 Million In Series C Financing
Vertex Pharma Enters Into Agreement With Mitsubishi Pharma
Synageva BioPharma Extends Co-Development Agreement With Mitsubishi Tanabe Pharma
Medicago Enters Into Co-Development Agreement With Mitsubishi Tanabe Pharma For Vaccines
Mitsubishi Tanabe Pharma Enters Into Co-Marketing Agreement With Daiichi Sankyo For MP-513 And TA-7284
Synageva BioPharma Enters Into Research Agreement With Mitsubishi Tanabe Pharma
Mitsubishi Tanabe Pharma Enters Into Co-Development Agreement With Kyoto University
Mochida Pharma Enters Into Co-Marketing Agreement With Mitsubishi Tanabe Pharma
deCODE biostructures Expands Research Agreement With Mitsubishi Tanabe Pharma
Affectis Pharma Enters Into Drug Discovery Collaboration With Mitsubishi Tanabe
GlaxoSmithKline Enters Into Co-Promotion Agreement with Mitsubishi Tanabe Pharma
Cellumen Enters Into Co-Development Agreement With Mitsubishi Tanabe Pharma
Mitsubishi Tanabe Enters Into Co-Marketing Agreement With Bayer Yakuhin
Mitsubishi Tanabe Amends Its Agreement With Novartis Pharma
Medarex Enters Into Research Agreement With Mitsubishi Pharma
Alfresa Pharma Enters Into Co-Marketing Agreement With Mitsubishi Tanabe
Alfresa Pharma Enters Into Co-Development Agreement With Mitsubishi Tanabe
Discovery Partners Enters Into Co-Development Agreement With Mitsubishi Pharma
Tanabe Seiyaku And Mitsubishi Pharma Complete Merger
Kureha Enters Into Licensing Agreement With Mitsubishi Tanabe
Mitsubishi Tanabe Enters Into License Agreement With R-Tech Ueno
Gedeon Richter Enters Into Licensing Agreement With Mitsubishi Pharma
Nuron Biotech Enters Into Licensing Agreement With Mitsubishi Tanabe For HibTITER
Mitsubishi Tanabe Pharma Enters Into Licensing Agreement With Toray For TRK-820
Dong-A Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For TALION
Daiichi Sankyo Enters Into Sub-Licensing Agreement With Mitsubishi Tanabe Pharma
Kowa Enters Into A Licensing Agreement With Taiwan Tanabe Seiyaku And P.T. Tanabe Indonesia
BioInvent Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma
Vertex Pharma Amends Agreement With Mitsubishi Tanabe Pharma
Mitsubishi Tanabe Enters Into Licensing Agreement With EnVivo Pharma
Mitsubishi Tanabe Enters Into Licensing Agreement With Cytochroma
Mitsubishi Tanabe Enters Into License Agreement With Maruho
Crucell And DSM Enter Into Licensing Agreement With Mitsubishi
Mitsubishi Tanabe Enters Into License Agreement With Centocor
Mitsubishi Tanabe Increases Its Stake In Choseido Pharma
Astellas Pharma Sells Hoshienu Pharma To Choseido Pharma

LIST OF FIGURES

Mitsubishi Tanabe Pharma Corporation – Pipeline by Indication, 2012
Mitsubishi Tanabe Pharma Corporation – Pipeline by Stage of Development, 2012
Mitsubishi Tanabe Pharma Corporation – Monotherapy Products in Pipeline, 2012
Mitsubishi Tanabe Pharma Corporation – Combination Treatment Modalities in Pipeline, 2012
Mitsubishi Tanabe Pharma Corporation – Pipeline By Therapeutic Class, 2012
Mitsubishi Tanabe Pharma Corporation - Pipeline By Target, 2012
Mitsubishi Tanabe Pharma Corporation – Pipeline By Route of Administration, 2012

Ask Your Question

Mitsubishi Tanabe Pharma Corporation – Product Pipeline Review – 2012

Date:	May 15, 2012
Pages:	131
Price:	US$ 500.00
License [?]:
Publisher:	Global Markets Direct
Report type:	Company Report
Delivery:	E-mail Delivery (PDF)
ID:	M7071D8D680EN
Leaflet:	Download PDF Leaflet

Company name*:
Contact person*:
Phone/fax*:
Email*:
	Request invoice
Your enquiry: